Compounds > c2-mycophenolic adenine dinucleotide
Page last updated: 2024-12-08

c2-mycophenolic adenine dinucleotide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

C2-mycophenolic adenine dinucleotide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID477579
CHEMBL ID410744
MeSH IDM0334106

Synonyms (14)

Synonym
[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-[[hydroxy-[2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1h-isobenzofuran-5-yl)ethoxy]phosphoryl]methyl]phosphinic acid
c2-mad
{[5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethoxy]-hydroxy-phosphorylmethyl}-phosphonic acid
{[5-(6-amino-purin-7-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethoxy]-hydroxy-phosphorylmethyl}-phosphonic acid mono-[2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-ethyl] ester
c2-mycophenolic adenine dinucleotide
bdbm19265
chembl410744 ,
c2-mycophenolic adenine dinucleotide (c2-mda)
[({[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)methyl][2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)ethoxy]phosphinic acid
[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-[[hydroxy-[2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1h-2-benzofuran-5-yl)ethoxy]phosphoryl]methyl]phosphinic acid
mono-[2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-ethyl] ester
{[5-(6-amino-purin-7-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethoxy]-hydroxy-phosphorylmethyl}-phosphonic acid
5'-o-[(r)-hydroxy({(s)-hydroxy[2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)ethoxy]phosphoryl}methyl)phosphoryl]adenosine
Q27463610
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Inosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)Ki0.25140.00600.12620.2600AID1060471; AID1797841; AID268955; AID303352; AID342523; AID580126; AID92749
Inosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)Ki0.32570.03300.16540.3300AID1060470; AID1797840; AID268954; AID303351; AID342522; AID580128; AID92608
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
GMP biosynthetic processInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
GTP biosynthetic processInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
circadian rhythmInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
lymphocyte proliferationInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cellular response to interleukin-4Inosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
'de novo' XMP biosynthetic processInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
GMP biosynthetic processInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
GTP biosynthetic processInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
nucleotide bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
DNA bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
RNA bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
IMP dehydrogenase activityInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
protein bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
metal ion bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
nucleotide bindingInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
nucleic acid bindingInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
DNA bindingInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
RNA bindingInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
metal ion bindingInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
IMP dehydrogenase activityInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
extracellular regionInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
nucleusInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cytoplasmInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
peroxisomal membraneInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cytosolInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
membraneInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
secretory granule lumenInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
extracellular exosomeInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
ficolin-1-rich granule lumenInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cytoplasmInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
extracellular regionInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
nucleusInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
cytoplasmInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
cytosolInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
secretory granule lumenInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
azurophil granule lumenInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
ficolin-1-rich granule lumenInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
cytoplasmInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID95607Concentration of the Antiproliferative compound required for the 50% inhibition of Growth against K562 cells2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Novel mycophenolic adenine bis(phosphonate) analogues as potential differentiation agents against human leukemia.
AID342522Inhibition of human IMP dehydrogenase 12008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Bis(sulfonamide) isosters of mycophenolic adenine dinucleotide analogues: inhibition of inosine monophosphate dehydrogenase.
AID303356Antiproliferative activity against human K562 cells after 72 hrs2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Probing binding requirements of type I and type II isoforms of inosine monophosphate dehydrogenase with adenine-modified nicotinamide adenine dinucleotide analogues.
AID1060476Antiproliferative activity against human HeLa cells2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
NAD-based inhibitors with anticancer potential.
AID580127Antiproliferative activity against human K562 cells after 72 hrs by MTS assay2011Bioorganic & medicinal chemistry, Mar-01, Volume: 19, Issue:5
Cofactor-type inhibitors of inosine monophosphate dehydrogenase via modular approach: targeting the pyrophosphate binding sub-domain.
AID580128Inhibition of human IMPDH1 by Spectrophotometry2011Bioorganic & medicinal chemistry, Mar-01, Volume: 19, Issue:5
Cofactor-type inhibitors of inosine monophosphate dehydrogenase via modular approach: targeting the pyrophosphate binding sub-domain.
AID1060470Inhibition of IMPDH1 (unknown origin)2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
NAD-based inhibitors with anticancer potential.
AID492854Inhibition of N-terminal His-tagged Mycobacterium tuberculosis H37Rv IMPDH2010Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
Triazole-linked inhibitors of inosine monophosphate dehydrogenase from human and Mycobacterium tuberculosis.
AID268955Inhibition of human IMPDH22006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Novel methylenephosphophosphonate analogues of mycophenolic adenine dinucleotide. Inhibition of inosine monophosphate dehydrogenase.
AID580126Inhibition of human IMPDH2 by Spectrophotometer2011Bioorganic & medicinal chemistry, Mar-01, Volume: 19, Issue:5
Cofactor-type inhibitors of inosine monophosphate dehydrogenase via modular approach: targeting the pyrophosphate binding sub-domain.
AID1060471Inhibition of IMPDH2 (unknown origin)2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
NAD-based inhibitors with anticancer potential.
AID303351Inhibition of human IMPDH type 12007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Probing binding requirements of type I and type II isoforms of inosine monophosphate dehydrogenase with adenine-modified nicotinamide adenine dinucleotide analogues.
AID268954Inhibition of human IMPDH12006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Novel methylenephosphophosphonate analogues of mycophenolic adenine dinucleotide. Inhibition of inosine monophosphate dehydrogenase.
AID95472Compound effect on differentiation of K562 cells, % of benzidine positive cells at 1.6 uM2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Novel mycophenolic adenine bis(phosphonate) analogues as potential differentiation agents against human leukemia.
AID342523Inhibition of human IMP dehydrogenase 22008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Bis(sulfonamide) isosters of mycophenolic adenine dinucleotide analogues: inhibition of inosine monophosphate dehydrogenase.
AID92749Inhibitory activity against human Inosine-5'-monophosphate dehydrogenase 2 (IMPDH type II)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Novel mycophenolic adenine bis(phosphonate) analogues as potential differentiation agents against human leukemia.
AID92608Inhibitory activity against human Inosine-5'-monophosphate dehydrogenase 1 (IMPDH type I)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Novel mycophenolic adenine bis(phosphonate) analogues as potential differentiation agents against human leukemia.
AID303352Inhibition of human IMPDH type 22007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Probing binding requirements of type I and type II isoforms of inosine monophosphate dehydrogenase with adenine-modified nicotinamide adenine dinucleotide analogues.
AID1060475Antiproliferative activity against human K562 cells2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
NAD-based inhibitors with anticancer potential.
AID95469Compound effect on differentiation of K562 cells, % of benzidine positive cells at 1.0 uM2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Novel mycophenolic adenine bis(phosphonate) analogues as potential differentiation agents against human leukemia.
AID1060473Antiproliferative activity against human HT-29 cells2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
NAD-based inhibitors with anticancer potential.
AID1797841IMPDH Type 2 Enzyme Assay from Article 10.1021/jm070568j: \\Probing Binding Requirements of Type I and Type II Isoforms of Inosine Monophosphate Dehydrogenase with Adenine-Modified Nicotinamide Adenine Dinucleotide Analogues.\\2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Probing binding requirements of type I and type II isoforms of inosine monophosphate dehydrogenase with adenine-modified nicotinamide adenine dinucleotide analogues.
AID1797840IMPDH Type 1 Enzyme Assay from Article 10.1021/jm070568j: \\Probing Binding Requirements of Type I and Type II Isoforms of Inosine Monophosphate Dehydrogenase with Adenine-Modified Nicotinamide Adenine Dinucleotide Analogues.\\2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Probing binding requirements of type I and type II isoforms of inosine monophosphate dehydrogenase with adenine-modified nicotinamide adenine dinucleotide analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (12.50)18.2507
2000's4 (50.00)29.6817
2010's3 (37.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.73 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
nad
[no description available]		2.0310NADgeroprotector
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		2.0410adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
thiazole-4-carboxamide adenine dinucleotide
thiazole-4-carboxamide adenine dinucleotide: structure given in first source		2.4420
mycophenolic acid
Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.		3.42702-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols		anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic
tiazofurin
tiazofurin: RN given refers to (beta-D)-isomer; structure given in first source. tiazofurine : A C-glycosyl compound that is 1,3-thiazole-4-carboxamide in which the hydrogen at position 2 has been replaced by a beta-D-ribofuranosyl group. It is metabolised to thiazole-4-carboxamide adenine dinucleotide (TAD), a selective inhibitor of inosine monophosphate dehydrogenase (IMP dehydrogenase).		2.43201,3-thiazoles;
C-glycosyl compound;
monocarboxylic acid amide		antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
prodrug
3-(1-deoxyribofuranosyl)benzamide
3-(1-deoxyribofuranosyl)benzamide: structure given in first source		2.0110
mycophenolate mofetil
mycophenolate mofetil : A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.		2.110carboxylic ester;
ether;
gamma-lactone;
phenols;
tertiary amino compound		anticoronaviral agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
immunosuppressive agent;
prodrug
nad
NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.		210organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Leucocythaemia
[description not available]		02.0110
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		02.0110